BACKGROUND: The purpose of this study is to examine outcome measures that assess functional mobility in adolescent survivors of osteosarcoma. We will also identify relationships between functional mobility measurements and specific measure(s) of health-related quality of life (HRQL). METHODS: Eighteen adolescent survivors of osteosarcoma at least 2 years from surgery at the Children's Hospital of Philadelphia (CHOP) participated in this study. Functional mobility, endurance, perceived exertion, and locomotor efficiency is examined with the following measurement tools: timed up and go (TUG), timed up and down stairs (TUDS), 9-min run-walk, rate of perceived exertion (RPE), and physiological cost index (PCI). The currently used evaluation of function from the American Musculoskeletal Tumor Society (MSTS) is also administered. The Short Form 36 (SF-36) measuring HRQL is used. RESULTS: MSTS scores did not correlate with quantitative functional outcome measures. MSTS scores did not correlate with the HRQL as measured by the SF-36. In contrast, subjects with a higher rate of vitality on the SF-36 walked with more efficiency, farther distance during the 9-min run-walk, and performed the TUDS and TUG with a faster speed. CONCLUSIONS: The MSTS does not correlate with actual measures of function or with HRQL. These data demonstrate the need for a new measure to determine functional mobility in survivors of osteosarcoma. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: The purpose of this study is to examine outcome measures that assess functional mobility in adolescent survivors of osteosarcoma. We will also identify relationships between functional mobility measurements and specific measure(s) of health-related quality of life (HRQL). METHODS: Eighteen adolescent survivors of osteosarcoma at least 2 years from surgery at the Children's Hospital of Philadelphia (CHOP) participated in this study. Functional mobility, endurance, perceived exertion, and locomotor efficiency is examined with the following measurement tools: timed up and go (TUG), timed up and down stairs (TUDS), 9-min run-walk, rate of perceived exertion (RPE), and physiological cost index (PCI). The currently used evaluation of function from the American Musculoskeletal Tumor Society (MSTS) is also administered. The Short Form 36 (SF-36) measuring HRQL is used. RESULTS: MSTS scores did not correlate with quantitative functional outcome measures. MSTS scores did not correlate with the HRQL as measured by the SF-36. In contrast, subjects with a higher rate of vitality on the SF-36 walked with more efficiency, farther distance during the 9-min run-walk, and performed the TUDS and TUG with a faster speed. CONCLUSIONS: The MSTS does not correlate with actual measures of function or with HRQL. These data demonstrate the need for a new measure to determine functional mobility in survivors of osteosarcoma. Copyright 2003 Wiley-Liss, Inc.
Authors: Christian Savio; Alberto Garaventa; Marina Gremmo; Riccardo Camoriano; Luca Manfredini; Sara Fieramosca; Giorgio Dini; Maurizio Miano Journal: Support Care Cancer Date: 2006-08-29 Impact factor: 3.603
Authors: Laura S Gilchrist; Mary Lou Galantino; Meredith Wampler; Victoria G Marchese; G Stephen Morris; Kirsten K Ness Journal: Phys Ther Date: 2009-01-15
Authors: Daphne Schreiber; Robert S Bell; Jay S Wunder; Brian O'Sullivan; Robert Turcotte; Bassam A Masri; Aileen M Davis Journal: Qual Life Res Date: 2006-05-27 Impact factor: 4.147
Authors: Janine Piscione; Wendy Barden; Janie Barry; Alexandra Malkin; Trisha Roy; Tyki Sueyoshi; Karen Mazil; Steven Salomon; Firas Dandachli; Anthony Griffin; Hugo Saint-Yves; Pina Giuliano; Abha Gupta; Peter Ferguson; Katrin Scheinemann; Michelle Ghert; Robert E Turcotte; Lucie Lafay-Cousin; Joel Werier; Caron Strahlendorf; Marc Isler; Sophie Mottard; Samina Afzal; Megan E Anderson; Sevan Hopyan Journal: Clin Orthop Relat Res Date: 2019-09 Impact factor: 4.176
Authors: Pamela S Hinds; Jami S Gattuso; Catherine A Billups; Nancy K West; Jianrong Wu; Cecilia Rivera; Juan Quintana; Milena Villarroel; Najat C Daw Journal: Eur J Cancer Date: 2009-05-18 Impact factor: 9.162
Authors: Pamela S Hinds; Catherine A Billups; Xueyuan Cao; Jami S Gattuso; Elizabeth Burghen; Nancy West; Jeffrey E Rubnitz; Najat C Daw Journal: Eur J Oncol Nurs Date: 2008-10-15 Impact factor: 2.398
Authors: Raheem J Paxton; Lee W Jones; Philip M Rosoff; Melanie Bonner; Joann L Ater; Wendy Demark-Wahnefried Journal: Psychooncology Date: 2010-09 Impact factor: 3.894
Authors: R Nagarajan; D R Clohisy; J P Neglia; Y Yasui; P A Mitby; C Sklar; J Z Finklestein; M Greenberg; G H Reaman; L Zeltzer; L L Robison Journal: Br J Cancer Date: 2004-11-29 Impact factor: 7.640